Browse by Poster Presenter

Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

H
Hahn, Erik

Pfizer
PI-013 - COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB + BINIMETINIB.
Erik Hahn
Favorite
Haj-Ibrahim , Houda
E-004 - EXTRAPOLATION OF EFFICACY OF A DEXTROAMPHETAMINE TRANSDERMAL SYSTEM (d-ATS) FROM PEDIATRIC (PED) TO ADULT POPULATIONS USING PHARMACOKINETIC (PK) MODELING.
Houda Haj-Ibrahim
Favorite
Hamilton, Riley

The University of Chicago
PI-024 - CHRONIC NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) USE INCREASES GASTRIC TOXICITY: A PHARMACOGENOMIC ANALYSIS.
Riley Hamilton
Favorite
Han, Xiaomei

US Food and Drug Administration
PII-068 - PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF OPIOID AND SEDATIVE/PSYCHOTROPIC DRUG EFFECTS ON VENTILATION AND PUPILLOMETRY.
Xiaomei Han
Favorite
Hartauer, Mattie

University of North Carolina at Chapel Hill
PII-095 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Mattie Hartauer
Favorite
PWI-005 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Mattie Hartauer
Favorite
Hohmann, Nicolas

National Center for Tumor Diseases
PI-017 - ELIGIBILITY CRITERIA OF EARLY PHASE ONCOLOGY TRIALS.
Nicolas Hohmann
Favorite
Hong, Eunjin

University of Southern California
PII-097 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Eunjin Hong
Favorite
PWI-001 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Eunjin Hong
Favorite
Huang, Robbie

Xeris Pharmaceuticals
LB-014 - POPULATION PHARMACOKINETIC ANALYSIS OF PHASE 1 SUBCUTANEOUS LEVOTHYROXINE FORMULATION (XP-8121).
Robbie Huang
Favorite
Hudson, Rachel

University of Utah
PII-120 - AN INTERIM PHARMACOKINETIC (PK) ANALYSIS OF CANNABINOIDS IN SERUM OF VOLUNTEERS RECEIVING COSMETIC HEMP EXTRACT VIA THE ORAL OR TOPICAL ROUTES.
Rachel Hudson
Favorite
Hughes, Emma

University of California, San Francisco
PT-007 - VALIDATING THE PROTECTIVE CONCENTRATION OF PIPERAQUINE FOR MALARIA PREVENTION IN PREGNANT UGANDAN WOMEN.
Emma Hughes
Favorite
Hunt, Porter

University of Utah
PT-001 - MAXIMUM LIKELIHOOD ESTIMATION OF RENAL TRANSPORTER ONTOGENY PROFILES FOR PEDIATRIC PBPK MODELING.
Porter Hunt
Favorite
Hwang, Sejung

Seoul National University College of Medicine and Hospital
PII-029 - THE EFFECTS OF RIFAMPICIN AS AN ORGANIC ANION TRANSPORTING POLYPEPTIDES INHIBITOR AND FEBUXOSTAT AS A BREAST CANCER RESISTANCE PROTEIN INHIBITOR ON PHARMACOKINETICS OF METHOTREXATE IN HEALTHY SUBJECTS.
Sejung Hwang
Favorite